Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX - Delayed Quote AUD

Mayne Pharma Group Limited (MYX.AX)

Compare
7.21
-0.02
(-0.28%)
At close: April 4 at 4:10:37 PM GMT+11

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.
NameTitlePayExercisedYear Born
Mr. Shawn Patrick O'Brien B.Sc CEO, MD & Director 1.5M -- 1960
Mr. Aaron Gray Chief Financial Officer 1.09M -- --
Ms. Kimberly Parker J.D. Executive VP & General Counsel -- -- --
Mr. Brant Schofield Executive Vice President of Corporate Development 1.04M -- 1966
Ms. Erinn Nathaniel Director of Global Human Resources -- -- --
Mr. Daniel Moore Executive Vice President of Specialty Products & Patient Solutions -- -- --
Dr. Frank Casty M.D. Executive VP & Global Chief Medical Officer -- -- --
Mr. Brenton Walter Financial Controller -- -- --
Ms. Laura Loftus Associate General Counsel & Company Secretary -- -- --

Mayne Pharma Group Limited

1538 Main North Road
Salisbury South, SA 5106
Australia
61 8 8209 2666 https://www.maynepharma.com
Sector: 
Healthcare

Description

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women's Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Corporate Governance

Mayne Pharma Group Limited’s ISS Governance QualityScore as of April 1, 2025 is 3. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 7; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 25, 2025 at 9:54 PM UTC

Mayne Pharma Group Limited Earnings Date

Recent Events

January 18, 2023 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers